Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Dinosaur collagen used to create one-of-a-kind handbag - 2Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- 3The 10 Most Compelling Forerunners in Innovation
- 4Criminal Guard Lawyer Expenses: What Would it be advisable for you to Hope to Pay?
- 5Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- Which European palace do you fantasy about visiting? Vote!
- Dependable Savvy Locks to Update Your Home Security
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Figure out How to Back Your Rooftop Substitution
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
- Understanding the Rudiments of Tree Administrations
- Archaeologists uncover details about the Hjortspring boat's origins
